Autolus Therapeutics
Price & Volume
Stats
See more52W Range | $1.10-$3.45 |
Market Cap | $364.6M |
Shares Short | 11M |
Financials
See moreRevenue (12 Mos) | $51.1M |
Revenue Growth (YoY) | -11% |
Gross Profit (12 Mos) | -$135.3M |
Diluted EPS | -$0.83 |
News
See moreYahoo Finance • 3 days ago
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
Yahoo Finance • 15 days ago
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Yahoo Finance • 16 days ago
Autolus outlines margin improvement and market share growth focus while expanding AUCATZYL to 60 U.S. centers
Yahoo Finance • 16 days ago
November 2025's Promising Penny Stocks To Watch
About
CEO | Dr. Christian Martin Itin Ph.D. |
CFO | Mr. Robert F. Dolski |
Address | The Mediaworks, London, United Kingdom, W12 7FP |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 647 |
